Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

We present a phase 2, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL-2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Discov
Hlavní autoři: Konopleva, Marina, Pollyea, Daniel A., Potluri, Jalaja, Chyla, Brenda, Hogdal, Leah, Busman, Todd, McKeegan, Evelyn, Salem, Ahmed Hamed, Zhu, Ming, Ricker, Justin L., Blum, William, DiNardo, Courtney D., Kadia, Tapan, Dunbar, Martin, Kirby, Rachel, Falotico, Nancy, Leverson, Joel, Humerickhouse, Rod, Mabry, Mack, Stone, Richard, Kantarjian, Hagop, Letai, Anthony
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436271/
https://ncbi.nlm.nih.gov/pubmed/27520294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0313
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky